Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Interventional × zanolimumab × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell 1

Interventions

Cisplatin 83 Fluorouracil 56 Gemcitabine 55 Paclitaxel 54 Docetaxel 54 Oxaliplatin 53 Capecitabine 53 Carboplatin 52 Cyclophosphamide 51 Radiotherapy 43 Drug Therapy 43 pembrolizumab 34 Leucovorin 31 Bevacizumab 31 Doxorubicin 29 Magnetic Resonance Spectroscopy 25 Dexamethasone 25 Cytarabine 24 Etoposide 23 Nivolumab 22 Pemetrexed 21 Methotrexate 21 Radiation 18 Vincristine 16 Trastuzumab 16 Irinotecan 16 apatinib 15 Prednisone 15 Letrozole 15 Folfox protocol 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00877656 2024-03-18

HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

Emergent BioSolutions

Phase 2/3 Completed

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡